Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

T3205

Sigma-Aldrich

Tamibarotene

≥98% (HPLC)

Sinônimo(s):

-((5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl)benzoic acid, 4-(((5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino)carbonyl)-benzoic acid, AM 80, AM80, AMNOLAKE, Amnoid, N-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl)-2-naphthyl)terephthalamic acid, N-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)terephthalamic acid, NSC 608000, UNII-08V52GZ3H9

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C22H25NO3
Número CAS:
94497-51-5
Peso molecular:
351.44
Número MDL:
MFCD00866188
Código UNSPSC:
12352200
ID de substância PubChem:
329826742
NACRES:
NA.77
Preço e disponibilidade não estão disponíveis no momento.

Nível de qualidade

100

Ensaio

≥98% (HPLC)

Formulário

powder

cor

white to off-white

solubilidade

DMSO: ≥10 mg/mL

temperatura de armazenamento

room temp

cadeia de caracteres SMILES

CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12

InChI

1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)

chave InChI

MUTNCGKQJGXKEM-UHFFFAOYSA-N

Aplicação

Tamibarotene has been used to study its mode of action and therapeutic potential.[1]

Ações bioquímicas/fisiológicas

Tamibarotene (Am80) is a RAR α agonist. Tamibarotene was developed to overcome resistance to ATRA and is currently approved in Japan for treatment of recurrent acute promyelocytic leukemia (APL). The compound induces HL-60 cells differentiation and apoptosis. Similarly to TTNPB, the compound neither binds to nor transactivates the RXRs. In contrast to TTNPB (pan RAR agonist), Tamibarotene is rather specific toward RAR α. The compound is approximate 10 times more potent than ATRA.
Tamibarotene is a synthetic retinoid drug, highly stable and potent inducer of differentiation than ATRA (all-trans retinoic acid).[2] It showed mild growth inhibition in myeloma cells and HUVECs (human umbilical vein endothelial cell).[3]

Características e benefícios

This compound is featured on the Nuclear Receptors (Non-Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Nota de preparo

Tamibarotene is soluble in DMSO at a concentration that is greater than or equal to 10 mg/ml.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
0000395647
0000395646
0000395647
0000395646
0000163494

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 1

1 of 1

Solução salina tamponada com fosfato pH 7.2, liquid, sterile-filtered, suitable for cell culture

SAFC

806544

Solução salina tamponada com fosfato

Hiroshi Keino et al.
Investigative ophthalmology & visual science, 52(3), 1548-1556 (2010-09-24)
To determine whether synthetic retinoic acid receptor (RAR)-α/β-specific agonist Am80 reduces inflammation in experimental autoimmune uveoretinitis (EAU). Naive CD4(+) T cells were activated with anti-CD3, anti-CD28, and transforming growth factor (TGF)-β, in the presence or absence of Am80. Intracellular expression
Hikaru Hattori et al.
PloS one, 13(10), e0204850-e0204850 (2018-10-06)
All-trans retinoic acid (ATRA) and arsenic trioxide (ATO) are essential for acute promyelocytic leukemia (APL) treatment. It has been reported that mutations in PML-RARA confer resistance to ATRA and ATO, and are associated with poor prognosis. Although most PML-RARA mutations
Xin Liu et al.
Journal of biomedical nanotechnology, 9(9), 1586-1593 (2013-08-29)
The present work evaluated the feasibility of nanostructured lipid carriers (NLC) for the intravenous delivery of tamibarotene (Am80), a poorly water-soluble drug for the treatment of acute promyelocytic leukemia (APL). The objective of this research was to develop a suitable
Hiroshi Fukasawa et al.
Biological & pharmaceutical bulletin, 35(8), 1206-1212 (2012-08-07)
Tamibarotene (Am80), a synthetic retinoid approved in Japan for treatment of acute promyelocytic leukemia (APL), is a retinoic acid receptor (RAR) agonist with high specificity for RARα and RARβ over RARγ. Temporarily and spatially specific expression of RARs suggests their
Ishido Miwako et al.
Drugs of today (Barcelona, Spain : 1998), 43(8), 563-568 (2007-10-11)
Tamibarotene is a new synthetic retinoid drug recently approved for relapsed or refractory acute promyelocytic leukemia (APL) in Japan. It is a specific agonist for retinoic acid receptor alpha/beta. Compared to all-trans retinoic acid (ATRA), a natural retinoid indicated for
Exibir todos os documentos relacionados

Artigos

Nuclear Receptors (Non-Steroids)

We offer many products related to non-steroid nuclear receptors for your research needs.

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica